Lapsed Mar 4, 2026 on the fee record · Medium confidence
20-year base term ends Apr 29, 2030
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,293,728, US 8,314,086), so the cap could be lower.
Third maintenance fee unpaid; grace period ended.
Apr 29, 2010
Mar 4, 2026
Mar 4, 2014
Feb 9, 2030
Its term would have run to Feb 9, 2030: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 29, 2010, when application 12/769,885, the earliest non-provisional in its chain, was filed (this one was filed Nov 26, 2012) | Apr 29, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,293,728, US 8,314,086, US 8,318,715, US 8,324,195, US 8,357,677, US 8,367,652, US 8,399,446, US 8,415,335, US 8,426,399, US 8,445,003, US 8,445,013, US 8,501,225) | capped to Feb 9, 2030 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | lapsed Mar 4, 2026 | High confidence |
| Computed term end | The steps above, in order | Mar 4, 2026 | Medium confidence |
This family
| US 8,298,554 | In force Oct 2030 | Oct 2030 |
| US 8,445,003 | In force Feb 2030 | Feb 2030 |
| US 8,454,994 | In force Apr 2030 | Apr 2030 |
| US 8,501,225 | In force Feb 2030 | Feb 2030 |
| US 8,445,013 | In force Feb 2030 | Feb 2030 |
| US 8,613,945 | Lapsed on the fee record Dec 2025 | Dec 2025 |
| US 8,663,662 | this patent Mar 2026 | Mar 2026 |
| US 8,623,406 | Lapsed on the fee record Jan 2026 | Jan 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 19, 2012 Reel 29499, frame 87 | Amarin Pharmaceuticals Ireland Limited | Biopharma Secured Debt Fund II Holdings Cayman LP | Security Agreement |
| Feb 27, 2013 Reel 29883, frame 497 | Manku, Mehar; Osterloh, Ian; Wicker, Pierre; Braeckman, Rene; Soni, Paresh | Amarin Pharmaceuticals Ireland Limited | Assignment of Assignor's Interest |
| Dec 20, 2017 Reel 44956, frame 395 | Biopharma Secured Debt Fund II Holdings Cayman LP | Cppib Credit Europe S.À R.L. | Patent Security Assignment and Assumption Agreement |
| Dec 21, 2017 Reel 44938, frame 257 | Amarin Pharmaceuticals Ireland Limited | Cppib Credit Europe S.À R.L. | Security Interest |
| Nov 19, 2020 Reel 54484, frame 552 | Cppib Credit Europe S.À R.L. | Amarin Pharmaceuticals Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,293,728, US 8,314,086, US 8,318,715, US 8,324,195, US 8,357,677, US 8,367,652, US 8,399,446, US 8,415,335, US 8,426,399, US 8,445,003, US 8,445,013, US 8,501,225.